阿替利珠单抗治疗合并特发性间质性肺炎的经治NSCLC的2期研究
该2期研究评估阿替利珠单抗单药在经治晚期或复发NSCLC合并特发性慢性纤维化间质性肺炎患者中的安全性和有效性,计划入组38例但因肺炎发生率高提前终止,实际入组17例;全部级别肺炎发生率29.4%,≥3级23.5%,5级5.9%,伴蜂窝肺患者≥3级肺炎发生率达57.1%。
要点
- 合并特发性间质性肺炎的经治NSCLC患者使用阿替利珠单抗肺炎风险增高
- 全部级别肺炎29.4%,≥3级23.5%,5级5.9%
- 伴蜂窝肺患者≥3级肺炎发生率为57.1%(4/7)
核心结论
- 符合本研究选择标准的合并特发性间质性肺炎的NSCLC患者可能具有更高的免疫检查点抑制剂诱导肺炎风险。
研究设计与样本
- 单臂2期研究,计划样本量38例,实际入组17例,因肺炎发生率高提前终止。
- 入组晚期或复发NSCLC合并特发性慢性纤维化间质性肺炎、用力肺活量大于70%且无免疫检查点抑制剂使用史的患者。
- 阿替利珠单抗1200 mg每3周给药直至满足停药标准,主要终点为1年生存率。
主要发现
- 17例患者中位年龄70岁,基线用力肺活量中位85.4%,一氧化碳弥散量中位54.4%。
- 全部级别肺炎发生率为29.4%(5/17),≥3级为23.5%(4/17),5级为5.9%(1/17)。
- 伴蜂窝肺患者≥3级肺炎发生率为57.1%(4/7),无蜂窝肺患者中仅1例(10%)发生1级肺炎(n=10)。
临床怎么用
- 对合并特发性间质性肺炎的经治NSCLC患者使用阿替利珠单抗前应充分评估肺炎风险,尤其需关注蜂窝肺表现。
局限性
- 研究因肺炎发生率高提前终止,实际样本量仅17例,远低于计划样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported to have a lower risk of pneumonitis than programmed cell death protein 1 inhibitors. This study aimed to assess the safety and efficacy of atezolizumab monotherapy in patients with pretreated advanced or recurrent NSCLC with idiopathic IP. METHODS: Patients with advanced or recurrent NSCLC with comorbid idiopathic, chronic fibrotic IP with % forced vital capacity of greater than 70% and no history of immune checkpoint inhibitors were enrolled. The patients received atezolizumab (1200 mg) every 3 weeks until the discontinuation criteria were met. The primary end point of this study was the 1-year survival rate. A sample size of 38 patients was set. RESULTS: This study was terminated early owing to high incidence of pneumonitis. A total of 17 patients were enrolled, with a median age of 70 years. The median % forced vital capacity and % diffusing capacity for carbon monoxide at baseline were 85.4% and 54.4%, respectively. The incidence of pneumonitis was 29.4% (5 of 17) for all grades, 23.5% (4 of 17) for grade greater than or equal to 3, and 5.9% (1 of 17) for grade 5. A total of 57.1% patients (4 of 7) with honeycomb lung developed pneumonitis with a grade greater than or equal to 3, whereas only one patient (10%) without honeycomb lung (n = 10) with grade 1 pneumonitis was found. CONCLUSIONS: Patients with NSCLC with comorbid IP as defined by the selection criteria for this study might have an increased risk of immune checkpoint inhibitor-induced pneumonitis.
引用
- Ikeda S, Kato T, Kenmotsu H, et al. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. J Thorac Oncol. 2020. PMID: 32858235. doi:10.1016/j.jtho.2020.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。